Google has unveiled the AlphaGenome Atlas, promising a high-resolution map of human DNA. While the announcement generated significant buzz, community discussions quickly turned to its licensing, with observers noting that non-commercial terms of service may serve to funnel lucrative drug discovery applications directly into Google's own commercial efforts like Isomorphic Labs.
For early-stage biotech and healthtech founders, this serves as a critical reality check on building around Big Tech infrastructure. Broad foundational maps are great for academic research, but restrictive commercial terms mean you cannot build a venture-backed startup directly on top of them without taking on massive platform risk.
For small backers investing from £500, the lesson is about defensibility over headline hype. Don't fund startups that are merely thin wrappers around Big Tech’s gated tools; instead, look for teams creating proprietary data pipelines, unique clinical access, or clear commercial moats that corporate giants can't easily shut down.